Foghorn Therapeutics (FHTX) Receivables (2021)
Foghorn Therapeutics (FHTX) posted quarterly Receivables of $300.0 million for Q4 2021.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Receivables (2021) Analysis & Trends
Foghorn Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $300.0 million for Q4 2021.
- In Q4 2021, Receivables changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2021 stood at $300.0 million (changed N/A YoY), while the FY2021 annual figure was $300.0 million, changed N/A from the prior year.
- Receivables for Q4 2021 stood at $300.0 million.
- The five-year high for Receivables was $300.0 million in Q4 2021, with the low at $300.0 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Foghorn Therapeutics | 346.08 Mn | 278.00 Mn | - | - |